Bionano Genomics heads into today's earnings report carrying meaningful short pressure — and a lending market that reinforces the bearish lean.
Short sellers hold nearly 11% of the free float, a substantial position for a micro-cap genomics company trading at $1.25. That figure has been drifting lower over the past month, falling roughly 5%, but the retreat has been gradual rather than a decisive cover. Days to cover of 9.8 give the position real exit risk if the stock moves sharply. The ORTEX short score holds at 69.6 — placing BNGO firmly in the elevated-short-pressure tier — and has been remarkably stable over the past two weeks, suggesting this is a settled rather than speculative position.
Availability tells a more nuanced story. About half the shares available to borrow have already been lent out, well below the 52-week peak of roughly 89.5% utilization hit earlier in the year. That means there is still room for new shorts to enter — this is not a constrained lending market — though cost to borrow at 7.9% signals that bearish conviction comes at a price. CTB has eased about 26% over the past week after a spike in early May, offering shorts a marginally cheaper entry point heading into the print.
The bull case here is essentially a momentum story: the stock is up more than 10% over the past month, a reversal from deeper losses, and BNGO beat estimates in its March report, sending the stock up 2.6% on the day. The bear case rests on the company's structural position — negative earnings yield, negative EV/EBITDA, and no analyst consensus data available. There is no analyst coverage to provide a formal target, which keeps institutional sponsorship thin. Heights Capital Management holds 10.2% of shares, a concentrated bet that has grown materially, but the next largest institutional holders are far smaller, reflecting limited broad-based conviction.
Insider activity from February showed the CEO, COO, General Counsel, and Chief Level Officer all selling shares — albeit in tiny dollar amounts, given the sub-$2 stock price. The EPS surprise percentile of 12 is weak, suggesting the company does not have a strong history of clearing the bar. The one prior reaction in the dataset — the March print — saw a one-day pop of 2.6% fade into a five-day loss of 1.7%, a pattern where initial relief gave way to selling pressure. The print today tests whether the month-long recovery in the stock price reflects durable optimism or a short-term squeeze that short sellers, still holding 11% of the float at a steady 9.8 days to cover, are positioned to fade.
See the live data behind this article on ORTEX.
Open BNGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
